Skip to content
TrialScanner

NCT03517176

CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer

Phase 1CompletedLSTALead

Registry record

Lead sponsor
Lisata Therapeutics, Inc.
Conditions
Pancreatic Cancer; Pancreatic Ductal Adenocarcinoma
Primary completion
Jun 19, 2020Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03517176 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03517176: CEND-1 in Combination With... | TrialScanner